Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / COM
-
Shares outstanding
-
66.4M
-
Number of holders
-
124
-
Total 13F shares, excl. options
-
56.6M
-
Shares change
-
-2.09M
-
Total reported value, excl. options
-
$1.01B
-
Value change
-
-$50.4M
-
Put/Call ratio
-
0.3
-
Number of buys
-
72
-
Number of sells
-
-42
-
Price
-
$17.84
Significant Holders of RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) as of Q1 2023
150 filings reported holding RYTM - RHYTHM PHARMACEUTICALS, INC. - COM as of Q1 2023.
RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) has 124 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56.6M shares
of 66.4M outstanding shares and own 85.17% of the company stock.
Largest 10 shareholders include PRIMECAP MANAGEMENT CO/CA/ (7.61M shares), BAKER BROS. ADVISORS LP (6.5M shares), RA CAPITAL MANAGEMENT, L.P. (5.52M shares), GOLDMAN SACHS GROUP INC (5.31M shares), FEDERATED HERMES, INC. (3.89M shares), NEA Management Company, LLC (2.91M shares), VANGUARD GROUP INC (2.65M shares), STATE STREET CORP (2.61M shares), Frazier Life Sciences Management, L.P. (2.16M shares), and ALKEON CAPITAL MANAGEMENT LLC (2.02M shares).
This table shows the top 124 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.